Your browser doesn't support javascript.
loading
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M; Hargis, Lauren; Engstrom, Lars D; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; David Lawson, J; Gunn, Robin J; Smith, Christopher R; Thomas, Nicole C; Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis; Bouhana, Karyn; Winski, Shannon; He, Leo; Fernandez-Banet, Julio; Pavlicek, Adam; Haling, Jacob R; Rahbaek, Lisa; Marx, Matthew A; Olson, Peter; Christensen, James G.
Affiliation
  • Hallin J; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Bowcut V; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Calinisan A; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Briere DM; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Hargis L; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Engstrom LD; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Laguer J; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Medwid J; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Vanderpool D; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Lifset E; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Trinh D; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Hoffman N; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Wang X; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • David Lawson J; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Gunn RJ; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Smith CR; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Thomas NC; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Martinson M; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.
  • Bergstrom A; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.
  • Sullivan F; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.
  • Bouhana K; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.
  • Winski S; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.
  • He L; Monoceros Biosystems, LLC, San Diego, CA, USA.
  • Fernandez-Banet J; Monoceros Biosystems, LLC, San Diego, CA, USA.
  • Pavlicek A; Monoceros Biosystems, LLC, San Diego, CA, USA.
  • Haling JR; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Rahbaek L; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Marx MA; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Olson P; Mirati Therapeutics, Inc., San Diego, CA, USA.
  • Christensen JG; Mirati Therapeutics, Inc., San Diego, CA, USA. christensenj@mirati.com.
Nat Med ; 28(10): 2171-2182, 2022 Oct.
Article in En | MEDLINE | ID: mdl-36216931
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2022 Document type: Article Affiliation country: Country of publication: